On Thursday, July 30, 2026, Profarma Distribuidora de Produtos Farmacêuticos S.A. (PFRM3) reported gross revenue of R$ 4.1 bn in the second quarter of 2026 (2Q26), representing growth of 31.4% compared to 2Q25, driven by the consolidation of two months of 4BIO.
In the same period, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) reached R$ 126.6 m, an increase of 25.4% versus 2Q25, with an EBITDA margin of 3.5%, a decrease of 0.2 percentage point. The group’s adjusted net income totaled R$ 31.7 m, an advance of 23.7% year over year.
The group’s gross margin was 14.9% in 2Q26, with gross profit of R$ 533.6 m, growth of 23.0% compared to 2Q25. Excluding the acquisition of 4BIO, the company reports that gross margin would have been 16.3%, an increase of 0.2 percentage point over the prior year.
Operating cash flow for the last 12 months reached R$ 395.7 m, up 84.6% from the period ended in 2Q25, while free cash flow came to R$ 206.4 m. Net debt closed 2Q26 at R$ 897.2 m, equivalent to 2.2 times adjusted EBITDA for the last 12 months, or 2.9 times when including 4BIO, with an average cost of CDI + 0.36%.
In the quarter, 4BIO’s consolidated cash conversion cycle was 58 days, a reduction of 5.4 days compared to 1Q26, and the group reported investments (capex) of R$ 197.9 m in the last 12 months, concentrated in the distribution operation, opening and remodeling of d1000 chain stores, and the structure of the specialty unit.
